Skip to content

Mounjaro vs Wegovy

By Dr Chad Okay4 min read

Different drugs. Mounjaro is tirzepatide (a dual GLP-1 + GIP agonist). Wegovy is semaglutide (GLP-1 only). In the SURMOUNT-5 head-to-head trial, tirzepatide produced more weight loss (20.2% vs 13.7% at 72 weeks). Side effect profiles are similar. Wegovy has more years of post-launch safety data. Both are weekly injections. On the NHS, Wegovy runs through specialist weight-management services (NICE TA875) while Mounjaro is in a phased rollout that includes primary care (NICE TA1026); most current UK users of either pay privately.

Mounjaro and Wegovy are the two most-prescribed GLP-1 drugs for weight loss in the UK right now. They look similar, work similarly, but they're different molecules with different efficacy and slightly different safety histories. Here's the actual head-to-head.

What's different

DetailMounjaroWegovy
Active drugTirzepatideSemaglutide
Drug classDual GLP-1 + GIP receptor agonistGLP-1 receptor agonist
ManufacturerEli LillyNovo Nordisk
Maximum dose15 mg weekly2.4 mg weekly
Average weight loss at 72 weeks20.2% (SURMOUNT-5 head-to-head)13.7% (SURMOUNT-5 head-to-head)
UK NHS accessNICE TA1026: phased rollout over 3 years, includes primary care, highest-need groups firstNICE TA875: specialist weight-management services, maximum 2 years
Years on market for weight lossFrom 2024From 2021

Why tirzepatide produces more weight loss

Tirzepatide activates two gut hormone receptors instead of one. GLP-1 is the same target as semaglutide. GIP is an additional gut hormone that influences insulin release, fat storage, and central appetite signalling. Activating both at once produces stronger effects on appetite suppression and metabolic improvement than GLP-1 alone. The trade-off was that tirzepatide is newer with less long-term safety data, but the data accumulating is reassuring so far.

SURMOUNT-5: the head-to-head trial

  • Published 2025. 751 adults with obesity, no diabetes.
  • 72 weeks of treatment.
  • Average weight loss: tirzepatide 20.2%, semaglutide 13.7%.
  • Tirzepatide users were more than twice as likely to lose 25% or more of body weight (about 32% vs 16%).
  • Side effect rates were broadly similar: nausea 46% on tirzepatide vs 44% on semaglutide, with GI issues most common during dose escalation.
  • Fewer people stopped tirzepatide because of gut side effects (2.7% vs 5.6%).
  • First randomised comparison; clear winner on weight loss.

What's the same

  • Schedule: both weekly injections.
  • Pen design: very similar.
  • Storage: refrigerated, room temperature once in use.
  • Dose ladder pace: both titrate up over 16-20 weeks to limit side effects.
  • Side effect profile: nausea, constipation, reflux, fatigue. In SURMOUNT-5, diarrhoea was identical (25% on both); Wegovy had slightly more constipation (31% vs 27%), more vomiting (21% vs 15%) and more reflux events.
  • Rare serious risks: pancreatitis, gallstones, severe gastroparesis on both. Severe, persistent abdominal pain needs same-day medical assessment, not a wait-and-see approach (see below).

Which one fits which situation

  • Maximum weight loss is the primary goal: lean Mounjaro on the SURMOUNT-5 evidence.
  • Longer track record matters more to you: Wegovy has 3+ extra years of post-launch use.
  • You've already responded well to Wegovy and tolerate it: probably no reason to switch.
  • You've not responded to Wegovy after 6+ months at 2.4 mg: switching to Mounjaro is reasonable.
  • You can't tolerate the GI effects of Wegovy: Mounjaro often (but not always) causes similar issues.
  • Cardiovascular outcomes evidence matters most (you have prior heart disease): Wegovy currently has more CV outcomes data; tirzepatide trials are still maturing.

If something feels wrong

This article is about comfort and everyday patterns, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.

Cost and access in the UK

  • NHS, Wegovy: through specialist weight-management services under NICE TA875 (BMI ≥35 plus at least one weight-related condition, or 30-34.9 meeting specialist referral criteria; maximum 2 years). Capacity is limited.
  • NHS, Mounjaro: NICE TA1026 (BMI ≥35 plus at least one weight-related condition) with a phased 3-year rollout that includes primary care, starting with the highest-need groups.
  • Both appraisals apply lower BMI thresholds (usually reduced by 2.5) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.
  • Private clinics: both around £150-300 per month depending on dose. Mounjaro often slightly cheaper at the lower-equivalent doses.
  • Pharmacy supply has been intermittent for both during the global demand surge. Mounjaro supply has been more stable since mid-2025.

Common questions

On weight loss, yes, SURMOUNT-5 was conclusive. On safety, similar profiles but Wegovy has more years of post-launch data. On cardiovascular outcomes, Wegovy has more evidence. So Mounjaro wins for weight loss specifically; Wegovy wins for established record. The right choice depends on what you're optimising for.

The wearable built to help you see your own patterns.

Designed to help you explore your everyday signals without keeping a diary. Bowel sounds, eating windows, sleep recovery.

Sources

  1. 1SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (2025), head-to-head trial, 20.2% vs 13.7% at 72 weeks, n=751, adverse events Table 3New England Journal of Medicine
  2. 2NICE TA1026: Tirzepatide for managing overweight and obesity (2024)NICE
  3. 3NICE TA875: Semaglutide for managing overweight and obesity, specialist weight management service, tiers 3 and 4 (2023)NICE
  4. 4Wegovy 2.4 mg SmPC, dose escalation to 2.4 mg over 16 weeks; nausea 43.9% over 68 weekselectronic Medicines Compendium (emc)
  5. 5SELECT trial, semaglutide cut MACE by 20% (HR 0.80) in overweight/obese CVD patients without diabetes (2023)PubMed Central
  6. 6Drugs@FDA: Wegovy (semaglutide) NDA 215256, original approval for chronic weight management 4 June 2021US Food and Drug Administration
  7. 7Mounjaro (tirzepatide) prescribing information: oral hormonal contraceptives and delayed gastric emptyingEli Lilly
  8. 8Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
  9. 9StatPearls: Compare and Contrast the GLP-1 Receptor Agonists (semaglutide, tirzepatide)NCBI Bookshelf / StatPearls
Written by Dr Chad Okay. Contributor: Dr Parisah Hussain, MBChB, BSc (Hons), DRCOG, MRCGP. Last updated . From Digests.

Read next

All Digests

About Digests

Digests explains how the body works in general, everyday terms. It is not medical advice. It is not a substitute for someone who can examine you and knows your history, and we do not tell you what dose of any medicine to take.

Where we describe how something is checked or looked after, we follow UK guidance from NICE and the NHS, so the tests and routes where you live may differ. The same concerns are worth taking to your own doctor.

Some articles explain approaches that researchers have studied, including gut-directed hypnotherapy. Explaining an approach is education, not an offer of it: Suna does not provide hypnotherapy or any medical or psychological treatment.

Suna Health is building a wearable wellness device for gut health and offers a gut-directed relaxation app, and you will see both advertised alongside these pages. That commercial interest does not decide what the content says.

If you think we have got something wrong, tell us at digests@suna.health. It goes to the editor. Full terms, including our liability position, are at suna.health/terms.

The wearable for gut health and nutrition. Built by a passionate team, grounded in peer-reviewed research.

Suna

Suna is a wellness device, not a medical or diagnostic device. It does not diagnose, treat, cure, or prevent any disease. The Suna app offers a five-week gut-directed relaxation program for general wellbeing. The program is a self-guided wellness practice: it is not medical care, not psychological treatment, and not hypnotherapy, and it is not a substitute for care from a qualified practitioner. Information provided is general wellness information, not medical advice. Always consult a qualified healthcare professional about any health concern.

Suna Health US, Inc., 2810 N Church St STE 90849, Wilmington, DE 19802

© 2026 Suna Health.